Medicine
Tivicay PD 5 mg tablet for oral suspension
Tivicay PD 5 mg tablet for oral suspension is a prescription medicine containing Dolutegravir for oral use, marketed by ViiV Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store TIVICAY tablets at 25°C (77°F), excursions permitted 15° to 30°C (59° to…
Key facts
- Active ingredient (INN)
- Dolutegravir
- Brand
- Tivicay PD
- Strength
- 5 mg
- Dosage form
- Tablet for oral suspension
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- ViiV Healthcare
- Manufacturer
- ViiV Healthcare
- Origin register
- US FDA, United States
- Storage
- Store TIVICAY tablets at 25°C (77°F), excursions permitted 15° to 30°C (59° to 86°F). Store TIVICAY PD tablets for oral suspension below 30°C (86°F). Store and dispense the 10-mg tablets in the original package, protect from moisture, and keep the bottle tightly closed. Store and dispense the 5-mg tablets in the original bottle, protect from moisture, and keep the bottle tightly closed.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AX12 Dolutegravir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 June 2020
- Identifiers
- RxCUI 1433873, 1433879, 1796077 +5DailyMed set ID 63df5af3-b8ac-4e76-9830-2dbb340af922NDC 49702-255Application NDA213983
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 60 tablet, for suspension in 1 bottle | 49702-255-37 | ViiV Healthcare | 12 June 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Dolutegravir
Clinical summary
Dolutegravir is a human immunodeficiency virus integrase strand transfer inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults (treatment-naïve or -experienced), among other approved uses. MedsAcross supplies Dolutegravir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DolutegravirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Tivicay prescribing information (ViiV Healthcare) · U.S. National Library of Medicine, DailyMed
- Tivicay: European public assessment report (EPAR) · European Medicines Agency
Need Tivicay PD 5 mg tablet for oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.